UP emerges as Medtech hub under Yogi government along Yamuna Expressway

Under the guidance of Chief Minister Yogi Adityanath, the UP government has taken another important step towards making the state a global centre for medical technology.

On the initiative of Invest UP, the Yamuna Expressway Industrial Development Authority (YEIDA) on Tuesday handed over a letter of intent for 10 acres of land to Shukra Pharmaceuticals Limited under the Medical Devices Park. The project is expected to generate over 900 direct and about 2,000 indirect employment opportunities. It is seen as a step towards taking Uttar Pradesh to new heights in advanced health innovation, the ‘Make in India’ initiative, and job creation.

Advertisement

Officials here on Tuesday said that Shukra Pharmaceuticals Limited will manufacture the world’s most advanced life-saving medical technologies at the state-of-the-art unit to be established in the Medical Devices Park. A major attraction of this project is the production of Boron Neutron Capture Therapy (BNCT) technology, which is considered an advanced method for the treatment of complex and serious cancer cases. This will help establish India in the forefront of global health innovation.

In this plant, a wide range of radiology and imaging equipment will be manufactured, including CT scanners, MRI, PET scans, X-ray, and ultrasonography machines. Along with this, respiratory care solutions necessary for anesthesia systems, ICUs, and operating theaters will also be developed, which will strengthen the health infrastructure not only of the state but across the country.

Under the project, advanced implants related to the heart, such as heart valves, stents, and left ventricular assist devices (LVAD), will also be manufactured, which will be life-saving for patients suffering from serious heart diseases. In addition, special attention will be given to the manufacture of respiratory support products like ventilators and oxygen concentrators.

Another major dimension of this Medtech Park is the development of medical robotic systems. Under this, soft tissue surgical robots, orthopaedic robotic systems (including implants), dental robotic systems, and neuro-spine robotic systems will be developed, which will promote a high level of precision, safety, and innovation in surgery.

Along with this, in-vitro diagnostic (IVD) solutions such as point-of-care testing devices and advanced analysers will be produced in this facility, enabling fast, accurate, and affordable testing for patients. To strengthen medical education and training, state-of-the-art medical simulators will also be established for doctors, nurses, and para-medical staff, which will promote skill development while reducing patient risk.

Through the project, more than 2,900 direct/indirect employment opportunities will be created. These will include manufacturing, research and development, quality control, regulatory services, sales, marketing, and support services. Special emphasis will be given to the recruitment of local youth and skill development in the project, which will ensure inclusive development.

On the occasion of handing over the letter of intent, YEIDA CEO Rakesh Kumar Singh and ACEO Shailendra Bhatia were present along with Shukra Pharmaceuticals Limited officials — Dr Minakshi Late (Group CEO and Global Head), Gaurav Shokin (Chief Operating Officer), Anil Kumar Verma (Vice President), and Kamini Bharti (Business Unit Head).